Nuvation Bio
NUVB· Manufacturing· Fiscal year ends in December
CEO pay in FY2025
David Hung, M.D. is the CEO of Nuvation Bio and was paid $3.9M in FY2025 (Dec), up 4%.
PayNo stock prices for these years
Executives3
See all- 1David Hung, M.D.President and Chief Executive OfficerFY2025
- 2Philippe SauvageChief Financial OfficerFY2025
- 3Gary Hattersley, Ph.D.Chief Scientific OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNuvation Bio paid its 2 named executives $5.4M in total in FY2025 (Dec). CEO David Hung, M.D. was paid $3.9M of that.
| Name | |||
|---|---|---|---|
| David Hung, M.D.President and Chief Executive Officer | |||
| Philippe SauvageChief Financial Officer | Not disclosed | ||
| Gary Hattersley, Ph.D.Chief Scientific Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Nuvation Bio. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Robert B. Bazemore, Jr.Lead independent director · 5 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance (Chair)—Paid as an executive
- Kim BlickenstaffDirector · 6 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 10, 2026 | FY2025 |
| Annual report | 10-K | Mar 2, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 8, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jul 30, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
